Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation

被引:148
作者
Diken, M. [1 ]
Kreiter, S. [1 ]
Selmi, A. [1 ]
Britten, C. M. [2 ,3 ]
Huber, C. [3 ]
Tuereci, O. [4 ]
Sahin, U. [1 ,2 ,3 ]
机构
[1] Inst Translat Oncol & Immunol TRON, D-55131 Mainz, Germany
[2] Johannes Gutenberg Univ Mainz, Div Translat & Expt Oncol, Dept Internal Med 3, Mainz, Germany
[3] BioNTech AG, Ribol, Mainz, Germany
[4] Ganymed Pharmaceut AG, Mainz, Germany
关键词
vaccination; dendritic cells; RNA; macropinocytosis; MESSENGER-RNA; IN-VITRO; DIRECT-INJECTION; PLASMID DNA; ANTIGEN; RESPONSES; RECEPTOR; TRIAL; ENDOCYTOSIS; MECHANISMS;
D O I
10.1038/gt.2011.17
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Even though it is known for more than one decade that antigen-encoding RNA can deliver antigenic information to induce antigen-specific immunity against cancer, the nature and mechanism of RNA uptake have remained enigmatic. In this study, we investigated the pharmacokinetics of naked RNA administered into the lymph node. We observed that RNA is rapidly and selectively uptaken by lymph node dendritic cells (DCs). Furthermore, in vitro and in vivo studies revealed that the efficient internalization of RNA by human and murine DCs is primarily driven by macropinocytosis. Selective inhibition of macropinocytosis by compounds or as a consequence of DC maturation abrogated RNA internalization and delivery of encoded antigens. Our findings imply that bioavailability of recombinant RNA vaccines in vivo highly depends on the density and the maturation stage of DCs at the administration site and are of importance for the design of RNA-based clinical immunotherapy protocols. Gene Therapy (2011) 18, 702-708; doi:10.1038/gt.2011.17; published online 3 March 2011
引用
收藏
页码:702 / 708
页数:7
相关论文
共 36 条
[11]   Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells [J].
Holtkamp, Silke ;
Kreiter, Sebastian ;
Selmi, Abderraouf ;
Simon, Petra ;
Koslowski, Michael ;
Huber, Christoph ;
Tureci, Ozlem ;
Sahin, Ugur .
BLOOD, 2006, 108 (13) :4009-4017
[12]   Suppression of RNA recognition by Toll-like receptors:: The impact of nucleoside modification and the evolutionary origin of RNA [J].
Karikó, K ;
Buckstein, M ;
Ni, HP ;
Weissman, D .
IMMUNITY, 2005, 23 (02) :165-175
[13]   mRNA is an endogenous ligand for Toll-like receptor 3 [J].
Karikó, K ;
Ni, HP ;
Capodici, J ;
Lamphier, M ;
Weissman, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) :12542-12550
[14]   THE FATE OF PLASMID DNA AFTER INTRAVENOUS-INJECTION IN MICE - INVOLVEMENT OF SCAVENGER RECEPTORS IN ITS HEPATIC-UPTAKE [J].
KAWABATA, K ;
TAKAKURA, Y ;
HASHIDA, M .
PHARMACEUTICAL RESEARCH, 1995, 12 (06) :825-830
[15]   Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals [J].
Kreiter, Sebastian ;
Selmi, Abderraouf ;
Diken, Mustafa ;
Sebastian, Martin ;
Osterloh, Phillip ;
Schild, Hansjoerg ;
Huber, Christoph ;
Tuereci, Oezlem ;
Sahin, Ugur .
JOURNAL OF IMMUNOLOGY, 2008, 180 (01) :309-318
[16]   Simultaneous ex vivo quantification of antigen-specific CD4 and CD8+ T cell responses using in vitro transcribed RNA [J].
Kreiter, Sebastian ;
Konrad, Thorsten ;
Sester, Martina ;
Huber, Christoph ;
Tuereci, Oezlem ;
Sahin, Ugur .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (10) :1577-1587
[17]   Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity [J].
Kreiter, Sebastian ;
Selmi, Abderraouf ;
Diken, Mustafa ;
Koslowski, Michael ;
Britten, Cedrik M. ;
Huber, Christoph ;
Tuereci, Oezlem ;
Sahin, Ugur .
CANCER RESEARCH, 2010, 70 (22) :9031-9040
[18]   Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo [J].
Kuhn, A. N. ;
Diken, M. ;
Kreiter, S. ;
Selmi, A. ;
Kowalska, J. ;
Jemielity, J. ;
Darzynkiewicz, E. ;
Huber, C. ;
Tureci, O. ;
Sahin, U. .
GENE THERAPY, 2010, 17 (08) :961-971
[19]   Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA [J].
Kyte, J. A. ;
Mu, L. ;
Aamdal, S. ;
Kvalheim, G. ;
Dueland, S. ;
Hauser, M. ;
Gullestad, H. P. ;
Ryder, T. ;
Lislerud, K. ;
Hammerstad, H. ;
Gaudernack, G. .
CANCER GENE THERAPY, 2006, 13 (10) :905-918
[20]   An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow [J].
Lutz, MB ;
Kukutsch, N ;
Ogilvie, ALJ ;
Rössner, S ;
Koch, F ;
Romani, N ;
Schuler, G .
JOURNAL OF IMMUNOLOGICAL METHODS, 1999, 223 (01) :77-92